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ABSTRACT
Trop2 is a transmembrane glycoprotein encoded by the Tacstd2 gene. It is 
an intracellular calcium signal transducer that is differentially expressed in many 
cancers. It signals cells for self-renewal, proliferation, invasion, and survival. It 
has stem cell-like qualities. Trop2 is expressed in many normal tissues, though in 
contrast, it is overexpressed in many cancers and the overexpression of Trop2 is of 
prognostic significance. Several ligands have been proposed that interact with Trop2. 
Trop2 signals the cells via different pathways and it is transcriptionally regulated 
by a complex network of several transcription factors. Trop2 expression in cancer 
cells has been correlated with drug resistance. Several strategies target Trop2 on 
cancer cells that include antibodies, antibody fusion proteins, chemical inhibitors, 
nanoparticles, etc. The in vitro studies and pre-clinical studies, using these various 
therapeutic treatments, have resulted in significant inhibition of tumor cell growth 
both in vitro and in vivo in mice. A clinical study is underway using IMMU-132 (hrS7 
linked to SN38) in patients with epithelial cancers. This review describes briefly 
the various characteristics of cancer cells overexpressing Trop2 and the potential 
application of Trop2 as both a prognostic biomarker and as a therapeutic target to 
reverse resistance.
INTRODUCTION
The transmembrane glycoprotein Trop2 is highly 
expressed in many cancers, but not all, and has differential 
expression in certain normal tissues. Trop2 is also known 
as trophoblast antigen 2, cell surface glycoprotein Trop-
2/Trop2, gastrointestinal tumor-associated antigen 
GA7331, pancreatic carcinoma marker protein GA733-
1/ GA733, membrane component chromosome 1 surface 
marker 1 M1S1, epithelial glycoprotein-1, EGP-1, CAA1, 
Gelatinous Drop-Like Corneal Dystrophy GDLD, and 
TTD2 [1,2]. It is coded by the gene Tacstd2. It is about 
35 kDa [3]. Trop2 spans the cellular membrane: it has 
an extracellular, a transmembrane, and an intracellular 
domain, along with a cytoplasmic tail essential for 
signaling [4].
Trop2 was first discovered in trophoblast cells. 
Trophoblast cells possess the ability to invade uterine 
decidua during placental implantation. Lipinski et al, [5] 
raised monoclonal antibodies against human neoplastic 
choriocarcinoma trophoblast cell lines via hybridoma 
technology. This led to the discovery of four new protein 
antigens (Trop1, 2, 3, and 4) expressed on normal and 
malignant trophoblast cells. Trop2 was reported to be 
expressed on syncytio- and cytotrophoblasts [5]. Trop2 
may analogously confer the capacity for proliferation 
and invasion to cancer cells [2,6]. Trop2 is expressed in 
the cytoplasm when cells become malignant and in some 
cases of cancer metastasis and recurrence [7].
Trop2 has been implicated in numerous intracellular 
signaling pathways. Trop2 transduces an intracellular 
calcium signal. Trop2-induced signal transduction can 
occur without extracellular Ca2+, suggesting a mobilization 
of Ca2+ from internal stores. Specific antibodies are used 
for cross-linking Trop2. This cross-linking leads to a 
significant rise in cytoplasmic Ca2+ [4]. Trop2 provides 
crucial signals for cells with requirements for proliferation, 
survival, self-renewal, and invasion [8]. Trop2 has several 
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ligands, inlcluding claudin-1, claudin-7, cyclin D1, and 
potentially IGF-1. Trop2 has stem cell-like qualities and 
regulates cell growth, transformation, regeneration, and 
proliferation, which explains why its overexpression can 
lead to tumor progression. It is expressed on the surface of 
many stem/progenitor cells and has a role in maintaining 
tight junction integrity [9].
Trop2 might be a modulator and/or an enhancer 
of EpCAM-induced cell signaling. Trop2 modulation of 
EpCAM can cause EpCAM to proliferate and migrate 
into liver parenchyma [4]. Trop2 can foster cell migration 
without the presence of growth factors. Induced foci 
formation represents a loss of the ability to maintain cell 
growth and movement [8].
Regulated Intramembrane Proteolysis (RIP) is 
required for Trop2 activity; it is necessary for Trop2’s 
enhanced cell growth and self-renewal activity in 
prostate cancer. RIP cleaves Trop2 through the TNF-α 
converting enzyme (TACE) followed by γ-secretase 
cleavage within the transmembrane domain. Cleavage is 
mediated by presenilin 1 (PS-1), which is the dominant 
enzyme, and presenilin 2 (PS-2). This cleavage makes two 
products, namely the extracellular domain (ECD) and the 
intracellular domain (ICD) [10].
The ECD is shed and found only on the plasma 
membrane and in the cytoplasm. Secreted ECD causes 
an increase in sphere size but not in sphere number, 
which suggests that the ECD increases the proliferation 
of progenitor cells, specifically of prostate stem cells. 
Treating prostate cells with secreted ECD leads to the 
appearance of small 6 kD fragments, suggesting Trop2 
cleavage. It is uncertain whether the ECD induces Trop2 
cleavage via distinct binding partner interactions or 
through direct hydrophilic interactions [10].
The ICD is released from the membrane, for the 
most part, and accumulates in the nucleus. Nuclear ICD 
is only detected in cancer specimens. Cleavage and 
activation is required for its transformation activity and 
it has been associated with human prostate cancer, but it 
could also be associated with other cancers [10]. The ICD 
is the functionally dominant part of Trop2. It promotes 
self- renewal, initiates prostatic intraepithelial neoplasia 
(PIN) and is involved in a β-catenin-dependent signaling 
cascade. Figure 1 shows the process of RIP activity and 
the interaction of the ICD with β-catenin [8].
The incomplete or aberrant production of Trop2 may 
Figure 1: Trop2-Regulated Intramembrane Proteolysis (RIP). RIP is required for Trop2 activity in prostate cancer. Trop2 is 
cleaved by the TNF-α converting enzyme (TACE), followed by y-secretase. The cleavage is mediated by the enzymes PS-1 and PS-2 in 
the complex. PS-1 is the dominant enzyme. Two products are made: the extracellular domain (ECD) is shed and is found on the plasma 
membrane and in the cytoplasm, and the intracellular domain (ICD) is released from the membrane and accumulates in the nucleus 
(although some is found on the membrane). The ICD is the functionally dominant part of Trop2 in prostate cancer. Within prostate cancer 
regions, β-catenin colocalizes with the ICD in the nucleus, leading to Trop2 proliferation. This process could possibly occur in other 
cancers. This colocalization causes upregulation of the downstream targets cyclin D1 and c-myc, which leads to cell growth [10].
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cause it to lose its function and to be internalized from 
the membrane into the cytoplasm, where it plays a role 
in cancer progression [7]. In GDLD, an accumulation of 
Trop2 is observed in the Golgi apparatus due to a defective 
transport [3]. When PIP2 is bound to the cytoplasmic tail 
of Trop2, phospholipase C (PLC) cleavage is important for 
Ca2+ release and for Trop2-mediated cell signaling and cell 
cycle progression [8]. Figure 2 shows this pathway. The 
exact mechanisms of Trop2 regulation and cell signaling 
have not been elucidated. 
Trop2 is reputed as a prognostic factor and a marker 
for numerous cancers. Trop2 mutations have been directly 
linked to GDLD but there are no known Trop2 mutations 
that have been implicated in cancers [3]. Trop2 has been 
reported to be overexpressed in the following solid tumor 
cancers: breast, cervix, colorectal, esophagus, gastric, 
certain lung cancers, squamous cell carcinoma of the oral 
cavity, ovary, pancreas, prostate, stomach, thyroid, urinary 
bladder, and uterus [11]. However, it has been reported 
to be underexpressed in non-small lung cancer [7]. Trop2 
is upregulated in several hematologic malignancies such 
as leukemia, extranodal nasal type lymphoma (ENK/TL), 
and Non- Hodgkin’s lymphoma (NHL), whereas no Trop2 
expression is found in anaplastic large cell lymphoma 
(ALCL) [12,13]. Currently, several antibodies, antibody 
drug conjugates, and inhibitors have been reported to 
target Trop2 expression with the objective of decreasing 
Trop2 overexpression and, thus, decreasing tumor 
progression in certain cancers (see below).
The Trop2 Gene
The gene that codes for Trop2 is called Tacstd2, 
Tumor-associated calcium signal transducer 2, and it is 
found on chromosome 1p32 [2]. It is about 35 kDa, with 
some sources documenting the size as 35.7 kDa and 35.79 
kDa [3]. Tacstd2 may be genetically and epigenetically 
regulated (see below for details). It has a CpG island, 
which is a DNA sequence of at least 200 base pairs with 
GC content above 50% and a ratio of CpG dinucleotide 
above 0.6, which covers a DNA fragment larger than 4 
kb and is located upstream of the transcriptional start site. 
Tacstd2 has 78 CpGs and 4 SP1 sites (GGGCGG) [7].
Figure 2: PLC Cleavage of PIP2 via Trop2 S303 Phosphorylation. If the cytoplasmic tail of Trop2 is bound to PIP2, it might 
be concentrating Trop2 for hydrolysis by phospholipase C (PLC). Once position S303 on the Trop2’s cytoplasmic tail is phosphorylated by 
protein kinase C (PKC), PIP2 is exposed for cleavage by PLC. It is uncertain whether S303 phosphorylation by PKC comes before increased 
Ca2+ concentration from Trop2 signaling or after or whether this phosphorylation itself releases PIP2 [4]. When PLC cleaves PIP2, this 
results in an increase of IP3 (inositol 1,4,5-triphosphate) in the cytoplasm and DAG (deacylglycerol) in the plasma membrane. IP3 causes 
Ca2+ release from the endoplasmic reticulum (ER) [82]. The increase in free Ca2+ and DAG could activate more PKC in a positive feedback 
mechanism. This increase in PKC could lead to further phosphorylation of Trop2 and activation of the Raf and NF-κB pathways [4]. Ca2+ 
release stimulates MAPK signaling and cell cycle progression [8].
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Trop2 is part of the GA733 family, which is 
composed of GA733-1 (Trop2) and GA733-2, which is 
also known as EpCAM (epithelial cell adhesion molecule). 
Trop2 might be a modulator and/ or an enhancer of 
EpCAM signaling [4]. Trop2 is intronless, while EpCAM 
is not and has 9 exons [14]. Trop2 and EpCAM have 
a very high structural similarity and a high sequence 
similarity; Trop2 has about 49% homology with EpCAM 
[9]. They are both type I transmembrane proteins with 
single transmembrane domains [14]. EpCAM has a role 
in cell-cell adhesion and cell signaling through c-myc 
and cyclin ATE, proliferation, migration, invasion, 
and differentiation. EpCAM overexpression has been 
correlated with poor prognosis in breast and ovarian 
cancers, but with increased survival in renal cell carcinoma 
[4]. In small-sized adenocarcinomas, Trop2 and EpCAM 
have opposite biological effects: Trop2 has an unfavorable 
outcome, while EpCAM has a favorable one [14].
Trop2 Domains
Trop2 is composed of several domains that span the 
cell membrane. It starts with a hydrophobic leader peptide 
that is made up of the first 26 amino acids [4]. The largest 
part of the molecule is the N- terminal extracellular part, 
also known as the ectodomain (Trop2EC). It is composed 
of 3 domains, anchored via a single transmembrane helix 
(TM) followed by a short intracellular tail of 26 amino 
acid residues (Trop2IC). The Trop2EC is composed of 
a small N-terminal cysteine-rich domain (CRD) as well 
as a cysteine-poor domain (CPD) [9]. Trop2 is predicted 
to have 4 N-linked glycosylation sites at the residues 33, 
120, 168, and 208 [4]. An extracelullar EGF (epidermal 
growth factor)-like repeat domain is made up of the 
amino acids 1-274 [4,7]. A thyroglobulin type-1 domain 
(TY) is located between amino acids 70-145, within the 
extracellular domain [4].
Trop2 extracellular domains (EC) contain 
globular portions with the GA733 type-I domain and a 
thyroglobulin type-IA motif, which are required for Trop2 
homomultimerisation. The cysteine free region acts as a 
stem to connect a globular moiety to single hydrophobic 
transmembrane segments. The short (25-26 amino acid 
long) intracytoplasmic C-terminal tail appears devoid of 
enzymatic domains.
The amino acids 275-297 make up the 
transmembrane domain (TM). Lastly, Trop2 has 
a cytoplasmic tail that has a phosphatidylinositol 
4,5-bisphosphate (PIP2)-binding motif, a conserved 
tyrosine site, and a serine phosphorylation site at S303. Part 
of Trop2 signaling is dependent on protein kinase C (PKC) 
and involves phosophyorylation of S303 [4].
The Trop2EC and Trop2IC are cleaved off of the 
TM in the process of regulated intramembrane proteolytic 
cleavage. The released Trop2IC indirectly influences 
cell proliferation and self-renewal through the β-catenin 
signaling pathway (see below) [9].
Trop2 Expression and Function in Normal Tissues
A. Role in Embryogenesis
Trop2 is expressed in trophoblast cells, which 
possess the capacity to invade uterine decidua during the 
process of placental implantation. The protein is highly 
expressed in these cells, which explains the origin of 
the Trop2’s name [4]. Trop2/ Tacstd2 is a marker highly 
enriched in spheroids and is expressed throughout the 
embryonic-day-14 intestinal epithelium. It is highly 
expressed in all epithelial proliferating progenitors of the 
E14 duodenum. Tacstd2 is among the most upregulated 
genes in spheroids versus organoids. At E15.5, Trop2 
is expressed in cells at the tip of the newly formed villi 
and the ileum, with a lower yet still detectable signal 
in the intervillus zone. Between E16.5 and birth, Trop2 
expressing cells progressively disappear, most likely by 
being shed from the villi [15].
In one report in which mTrop2/ EpCAM is knocked 
out in mice, the mice were born alive, but they died soon 
after birth because of an inability to gain weight as well 
as experiencing hemorrhagic diarrhea, thus showing the 
necessity of Trop2 in early development and survival [16].
B. Role in Fetal Growth
Trop2 has been found to be upregulated during 
accelerated fetal lung growth/expansion. In one study, an 
induced 75% reduction in Trop2 expression led to a 50% 
decrease in the percentage of proliferating fibroblasts. 
Thus, Trop2 may have a role in regulating normal fetal 
lung growth. As organogenesis and tumorigenesis are 
thought to share common regulatory pathways, it is 
hypothesized that Trop2 may promote cell proliferation 
in the developing lung.[1] Trop2/Cnx43+ cells act as 
transient stem cells responsible for the generation of fetal 
intestine in an environment with low Wnt and high Bmp 
stimulatory tones, which prevail at this period of intestinal 
development [15].
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C. Expression in Normal Tissues
Trop2 is expressed in a number of normal tissues, 
which is important to note when considering the targeting 
of Trop2 expressing cancer tissues. In fetal rat lungs, 
Trop2 is mainly expressed in type II alveolar epithelial 
cells (AECs), interstitial fibroblasts, smooth muscle 
cells, myofibroblasts, and airway epithelial cells [1]. 
Membrane localized expression of Trop2 has been noted 
in stratified squamous, cuboidal, and columnar epithelial 
cells. Trop2 has been expressed, albeit at different levels, 
in the following normal (non-cancerous) tissues: the 
epithelial barrier/lining of the stratum basale epidermis, 
breast, cervix, cornea, the epithelial secretory tissue of 
the endocrine and exocrine glands, esophagus, heart, 
kidneys (distal convoluted tubules and collecting ducts), 
larynx, lung, liver, pancreas, prostate, salivary gland, skin, 
thymus, tonsils, trachea, trophoblast cells, urothelium, and 
uterus [11].
Trop2 Binding Partners
Several reports have shown that Trop2 binds to 
several factors, such as IGF-1, claudin-1 and 7, cyclin D1, 
and PKC, and these are briefly described below.
A. IGF-1 
IFG-1 (insulin-like growth factor 1) might be a 
ligand of Trop2, allowing it to activate its
putative downstream mediators (PIP2 and Ca2+ ) and 
modulate IGF-1R signaling. Trop2’s phosphatidylinositol 
4,5-bisphosphate (PIP2)-binding domain contains a 
phosphorylation site (S303) and an extracellular EGF-like 
and thyroglobulin type-1 repeat domain. Trop2’s PIP2-
binding domain may bind IGF-1 and, thus, outcompete 
the IGF-1 binding protein. Another possibility for Trop2’s 
function is that it may form a complex with IGF-1 and, 
thus, prevents IGF-1R signaling [7].
B. Claudin-1 and Claudin-7
The transmembrane proteins claudin-1 and 
claudin-7 are binding partners of the Trop2 ectodomain 
(EC). They play important roles in tight junctions at the 
epithelial barrier. Trop2 is speculated to act as an anchor 
or as a transporter during claudin rearrangement or it may 
function as a stabilizer to prevent claudin degradation via 
the ubiquitin-proteasome system [9].
Trop2 is important in maintaining the tight junction 
integrity as well. Trop2 might indirectly affect adhesive 
interactions between proteins because it can modulate 
cell adhesion to fibronectin through the P1 integrin/
RACK1 (receptor for activated protein kinase C) complex 
formation [9]. Loss of Trop2 leads to decreased expression 
and rearrangement of the subcellular localization of 
certain proteins, which affect the performance of the 
epithelial barrier. This is specifically noted in the GDLD. 
The claudin-4 protein is thought to reside closely next 
to Trop2, via a side-by-side or head-to-head interaction 
with the claudin-1 or claudin-7 protein, but it does not 
bind Trop2. Trop2 and claudins-1 and -7 are thought to 
bind to each other through their AxxxG motifs because 
EpCAM binds claudin-7 through this interaction. The 
exact mechanism is unclear [17].
C. Cyclin D1
Trop2 forms an oncogenic fusion protein with cyclin 
D1 [18]. Bicistronic cyclin D1-Trop2 mRNA arises from 
the posttranscriptional joining of the cyclin D1 transcript 
at the poly-adenylation site in exon V with the full-length 
Trop2 mRNA, leading to the independent expression of 
both proteins. The appearance of the bicistronic mRNA 
occurs by the intermolecular splicing in trans of the two 
mRNAs. The binding of the 2 mRNA molecules increases 
the stability of cyclin D1 when compared to its normal-
full length transcript. This chimera is expressed by human 
tumors differentially. Low amounts of the chimera are 
enough to increase the life span and cell proliferation of 
senescent primary cells [4]. The chimeric cyclin D1-Trop2 
protein is implicated in cell transformation; silencing this 
fusion protein inhibits tumor growth [7].
D. PKC
The HIKE region of Trop2 binds to protein kinase 
C (PKC) and is phosphorylated by PKC. HIKE is a 
highly conserved sequence motif identified as a candidate 
pleckstrin-homology (PH) domain binding site in GP 
proteins, protein kinases, ankyrin and kinesin. PKC 
regulates the binding of downstream effectors to target 
sequences of phosphorylation at S/T residues [3]. PKCa 
is an isoform of PKC that interacts with the tail of Trop2. 
It is activated by Ca2+ and deacylglycerol (DAG) and is 
translocated to the plasma membrane. Activation of PKCa 
is necessary for podosome formation.
PKC phosphorylates Trop2’s cytoplasmic tail at 
the S303. PIP2 (phosphatidylinositol 4,5- bisphosphate) 
has been suggested to regulate the phosphorylation of 
S303 by PKC. If the cytoplasmic tail of Trop2 is bound to 
PIP2, it might be concentrating Trop2 for hydrolysis by 
phospholipase C (PLC). When position S303 is activated 
or phosphorylated, the binding of the cytoplasmic tail to 
PIP2 might be reversed. This exposes PIP2 for cleavage 
by PLC, which results in an increase of IP3 (inositol 
1,4,5-trisphosphate), DAG (deacylglycerol), and Ca2+ 
release from the endoplasmic reticulum. The increase in 
free Ca2+ and deacylglycerol could activate more PKC 
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in a positive feedback mechanism, which could lead to 
the phosphorylation of more Trop2 and the activation 
of the Raf and NF-κB pathways by PKC (Figure 2). It 
is uncertain whether the phosphorylation of S303 comes 
before or after the increased Ca2+ concentration from 
Trop2 signaling or whether the phosphorylation of S303 
releases PIP2 [4].
Cell Signaling Mediated by Trop2
Trop2 upregulation drives the expression and 
activation of CREB1 (cyclic AMP-responsive element 
binding protein), Jun, NF-κB, Rb, STAT1 and STAT3 
through induction of the cyclin D1 and the ERK 
(extracellular signal regulated kinase)/MEK (MAPK/ERK 
kinase) pathways. Growth- stimulatory signaling through 
NF-κB, cyclin D1 and ERK were shown to require an 
intact Trop2 cytoplasmic tail; its deletion abolishes 
stimulation of growth and modulation of NF-κB, cyclin 
D1 and pERK [19].
Trop2 has a HIKE-like phosphoinositide-binding 
motif, which is frequently present in signal transducers and 
can act as a docking site for regulatory/effector molecules 
[19]. The HIKE region (highly conserved sequence motif 
identified as a candidate pleckstrin-homology (PH) domain 
binding site in GP proteins, protein kinases, ankyrin and 
kinesin) may have a regulatory role in protein- protein and 
protein-lipid bindings [3].
Trop2 causes activation of the ERK1/3-MAPK 
pathways, which both govern cell cycle progression 
and may protect cancer cells from apoptosis [7]. Trop2 
might indirectly affect adhesive interactions since it can 
modulate cell adhesion to fibronectin through the P1 
integrin/RACK1 complex formation [9].
Trop2 potentially plays a role in deregulating 
characteristic stem cell proliferation and differentiation 
pathways such as Notch, hedgehog, and Wnt [8]. 
Trop2 functionally regulates adult tissue self-renewal 
and prostate regeneration [10]. Aberrant glycosylation 
of CD133 or Trop2 in prostate cancer stem cells may 
affect their folding and stability, resulting in incorrect 
protein assembly and abnormal signaling networks, 
thus promoting cancer growth [20]. mTrop2 expression 
leads to increased levels of phosphorylated p42/p44 
MAPK (ERK1/ERK2), which are master regulators of 
the transition from the G1 to the S-phase. Cyclin D1 and 
cyclin E are downstream targets of the ERK/ MAPK 
pathway and they are involved in the termination of the 
G0-G1 cell cycle arrest and the initiation and progression 
of the S phase. Thus, mTrop2 expression results in 
increased cell proliferation at low serum concentrations 
with an increased percentage entering the DNA synthesis 
phase [8].
Podosomes are actin-rich adhesion structures that 
control the activity of matrix metalloproteinases. They are 
thought to contribute to matrix remodeling and to serve as 
adhesion locations for invasive cells. Activation of Trop2 
could indirectly lead to podosome formation by increasing 
the intracellular calcium concentration required to activate 
PKCa which could then phosphorylate Trop2 and signal 
via Src, Cdc42, and RhoaA to induce the formation of 
podosomes [4]. 
A. Trop2-Mediated MAPK Signaling 
mTrop2 expression can lead to MAPK signaling 
activation. The MAPK pathway can be further stimulated 
by an increase in Ca2+. MAPK signaling results in 
the induction of the AP-1 transcription factor and the 
downregulation of p27, which is a cyclin-dependent kinase 
inhibitor 1B. P27 binds to and prevents activation of cyclin 
D1-CDK4 to cyclin E-CDK4 complexes. Expression 
of mTrop2 is correlated with increased expression of 
the proliferation marker Ki-67. Downstream targets of 
MAPK are cyclin D1 and cyclin E. Figure 3 demonstrates 
the Trop2-mediated MAPK signaling pathway. mTrop2 
increases the levels of phosphorylated MAPK (ERK1/
ERK2) and, thus, mediates cell cycle progression. 
Increased levels of cyclin D1 and cyclin E help mediate 
cell cycle progression. An increase in intracellular calcium 
from internal stores could have an effect on cell signaling 
activation and on the activation and progression of the 
cell cycle through activation of PKC and/or the calcium/
calmodulin-dependent protein kinase II (CaMKII). An 
increased percentage of cells, thus, enters the S phase. 
Activation of ERK is observed in several cancers and in 
cells that overexpress human Trop2. Heightened ERK 
activity could induce the phosphorylation of FOXO3a 
at residues S294, S344, and S425. This can cause its 
ubiquitination by MDM2, which then promotes FOXO3a’s 
cytoplasmic localization and proteasomal degradation. 
The interaction between the ERK pathway and FOXO3a 
is reported to promote cell growth and tumorigenesis. 
It is uncertain whether Trop2-induced activation of 
ERK directly results in FOXO3a degradation. ERK1/2 
activation could be providing anti- apoptotic signals which 
promote tumor cell survival [8].
B. Trop2-Mediated IGF-1R Signaling in Lung 
Cancer
High Trop2 expression attenuates IGF-1R signaling, 
which suppresses lung cancer growth and malignancy. 
IGF-1 might be a ligand of Trop2, allowing it to activate 
downstream mediators (PIP2 and Ca2+) and modulate IGF-
1R signaling. Another possibility is that the extracellular 
EGF-like and thryoglobulin type-1 repeat domains of 
Trop2 may form a complex with IGF-1 and, thus, mediates/
suppresses IGF-1R signaling. During lung development, 
Trop2 acts as an attenuator of the IGF-1/IGF-1R signaling 
pathway whereby the ECD competes with the IGF-1 for 
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IGF-1 binding [9]. Trop2 downregulates signaling by 
trapping IGF-1 in the surrounding microenvironment and, 
thus, outcompeting IGF-1R, which inhibits activation of 
IGF-1R signaling-mediated gene expression.
Trop2 signals through β-catenin (downstream targets 
cyclin D1 and c-myc get upregulated). Trop2’s function 
requires the presence of β-catenin. β-catenin colocalizes 
with ICD within the nucleus. This is restricted to cancer 
regions and does not occur in benign tissues [10].
Downstream of this IGF-1/ IGF-1R downregulation, 
the AKT/ERK gene, β-catenin, and slug expressions are 
suppressed. Trop2 may regulate activites of AKT and 
ERK depending on the histotypes of cancer cells. When 
there is less Trop2 expression on the membrane, this could 
reduce IGF-1R signaling-mediated AKT/ β-catenin /slug 
expression and ERK activation through a direct binding 
of IGF-1 [7].
Transcriptional Regulation of Trop2 Expression
A. Transcription factors of Trop2
1. CREB1 
The Tacstd2 gene has a switch-like behavior, with 
CREB1 as a possible regulator. CREB1 is activated in 
breast cancer and modulates the transcription of Tacstd2. 
At the same time, the activation of Tacstd2 increases the 
cytoplasmic calcium (Ca2+) level, which could in turn 
activate CREB1 through calmodulin-dependent protein 
kinases (e.g. CaMKII). The activated CREB1 could bind 
to the promoter of Tacstd2, and form a positive feedback 
system to promote and maintain the on state of Tacstd2 
[21].
Figure 3: mTrop2 Cell Signaling and Resulting Activities. mTrop2 expression increases the expression of the proliferation marker 
Ki-67 and causes Ca2+ to be mobilized from internal stores. mTrop2 expression downregulates p27 (cyclin-dependent kinase inhibitor 1B). 
mTrop2 expression activates MAPK signaling, which increases levels of phosphorylated ERK1 and ERK2. MAPK signaling and cell cycle 
progression can be further stimulated by Ca2+. mTrop2 increases levels of cyclin D1 and cyclin E, which help mediate ERK1/2 cell cycle 
progression (an increased percentage of cells enter the S phase). ERK signaling leads to induction of the AP-1 transcription factor [8]. It 
is a central regulator of tumor-associated target genes during carcinogenesis. AP-1 causes angiogenesis via VEGF (vascular endothelial 
growth factor), cell proliferation via the cyclins and CDKs, apoptosis via pro-apoptotic bcl-2 (B-cell lymphoma 2) or FasL (Fas ligand), 
and causes cell invasion and metastasis via MMPs (matrix metalloproteinases), Pdpn (podoplanin), Ezrin, and CD44, and it causes the 
epithelial to mesenchymal transition (EMT) via Pdpn. The EMT allows for the nuclear translocation of β-catenin, which causes cell growth 
via β-catenin’s downstream effectors [26]. Heightened ERK activity could induce phosphorylation of FOXO3a at residues S294, S344, 
and S245, which can lead to ubiquitination by MDM2 (mouse double minute 2) and subsequent cytoplasmic localization and proteasomal 
degradation [8]. FOXO3a can induce cell death, therefore, its degradation could help promote cell survival in cancer [39].
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2. NF-κB 
NF-κB and Trop2 have regulatory roles on each 
others’ expression levels. Experiments in human breast 
cancer cell lines have shown that Trop2 gene expression 
is downregulated within a couple of hours of either the 
inhibition of NF-κB’s protein activity or by its reduction 
in translocation, which confirms a regulatory role of NF-
κB on the transcription of the Trop2 gene. There is, thus, 
a potential positive feedback system between NF-κB and 
Trop2 that supports the ‘switching’ behavior of Trop2 
expression, which was uncovered in a previous analysis 
[21].
3. HOXA10 
HOXA10 (homeobox) is known to downregulate 
Trop2 expression [22]. It is involved in the proliferation 
of hematopoietic stem cells and progenitor cells. Its over-
expression is associated with cancer development and 
poor prognosis in patients with acute myeloid leukemia 
and solid cancers [23].
The HOXA10 promoter has an NF-κB -binding 
site. NF-κB expression can lead to inflammation and 
carcinogenesis [23]. Trop2 phosphorylation can lead to 
downstream NF-κB activation [4]. Thus, it is possible that 
Trop2 downregulation by HOXA10 may decrease NF-κB 
activation, which can thus decrease the NF-κB -binding to 
the HOXA10 promoter, which could lead to a decrease in 
cancer progression.
B. Trop2 expression is further modulated by the 
inactivation of the following transcription factors
1. TCF-1/LEF-1/HNF1A 
The Lymphoid enhancer factor, (LEF1)/ T-cell factor 
(TCF-1)/ hepatocyte nuclear factor 1 (HNF1A) acts as a 
feedback transcriptional repressor of the β-catenin -TCF-4 
target genes. Disruption of this negative feedback induces 
the formation of intestinal tumors. HNF1A/TCF-1 is the 
largest hub in the Trop2 transcription network and is 
essential for stem-cell growth [19].
When appropriate extracellular signals are delivered 
to an epithelial cell, β-catenin accumulates in a form 
that is able to be transported to the nucleus, where it 
can associate with hTCF-4 (a form of TCF expressed in 
normal colonic epithelium). Interaction of hTCF-4 with 
β-catenin results in transcriptional activation. The genes 
that are activated—possibly Trop2—may participate 
in the generation and turnover of epithelial cells. The 
disruption of β-catenin -TCF signaling may be an early 
step in malignant transformation [24]. If the accumulated 
β-catenin is found in the nucleus, it may potentially bind 
Trop2 and lead to cancer progression, suggesting that TCF 
disruption may be a positive regulator of Trop2.
2. TP63/TP53L 
The tumor protein 63 (TP63)/ tumor protein 
53L (TP53L), a homologue of the tumor suppressor 
p53 drives the expression of genes involved in cell 
adhesion, proliferation, and death [19]. p63 is a positive 
prognostic factor in cancer progression and outcome. The 
predominant isoform, ΔNp63α, can act as a transcriptional 
repressor, possibly of Trop2. It is overexpressed in a 
number of epithelial cancers. By maintaining the epithelial 
character of cancer cells, ΔNp63α may act like a supressor 
of cancer metastasis, which is a similar role of normal 
Trop2 expression [8,25]. At the same time, ΔNp63α may 
possibly act to promote early steps in tumorigenesis by 
protecting cells from growth arrest and apoptosis, yet still 
allowing cells the plasticity necessary for physiologic and 
pathologic epithelial to mesenchymal transitions (EMT) 
[25]. The EMT leads to loss of cell-cell adhesion, loss 
of apical-basal cell polarity, increased motility of cells, 
loss of epithelial markers such as E-cadherin, gain of 
mesenchymal markers such as vimentin, and acceleration 
of TGF-β signaling [26]. Activation of β-catenin signaling 
is another function. Loss of p63 expression predisposes 
to a loss of epithelial characteristics and acquisition of 
mesenchymal characteristics, resulting in up-regulation of 
genes associated with tumor invasion and metastasis [2].
3. ERG 
ERG (ETS-related gene), of the ETS (erythroblast 
transformation- specific) family, regulates endothelial 
cell-adhesion molecules and interleukin 8 [19]. It is 
required for embryonic stem cell (ESC) differentiation 
toward the endothelial fate and it regulates angiogenesis 
and endothelial apoptosis. The growth promoting effects 
of ERG suggest that aberrant regulation of ERG could 
play an important role in the development of leukemia 
and other cancers. ERG has 36,000 target regions 
and participates in a complex harboring several other 
transcription factors associated with normal hematopoietic 
development. Trop2 could possibly be a target gene of 
ERG. Post-translational modifications of ERG could lead 
to cancer progression [27]. Inactivation of ERG may have 
a correlation with upregulation of Trop2 in certain cases 
and, thus, cancer progression.
4. GRHL3
GRHL-1/Get-1 (grainyhead-like epithelial 
transactivator) belongs to a large family of genes 
encoding developmental transcription factors. GRHL3 
is expressed in human endothelial cells and is required 
for endothelial and epidermal cell migration, which is 
similar to the function of Trop2 [28]. When mutated, it 
affects multiple genes linked to terminal differentiation 
and possibly Trop2 [19]. GRHL3 activates ERK1 and 
ERK2—as does Trop2—which are known inductors of 
proliferation, in keratinocytes. GRHL3 overexpression 
increases Akt phosphorylation [28]. In lung cancer, 
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Trop2 actually attenuates IGF-1R signaling-mediated 
AKT expression and, thus, has the opposite effect [7]. 
GRHL3 increases Akt and eNOS (endothelial nitric oxide 
synthase) activation, which are both required for apoptosis 
protection. Loss of GRHL3 may result in endothelial 
dysfunction, due to loss of its anti-apoptotic effect [28].
5. PU.1
SPI1/PU.1 (spleen focus forming virus [SFFV] 
proviral integration oncogene) functions in germinal 
progenitors [19]. PU.1 is the hallmark ETS factor involved 
in hematopoiesis and is a regulator of gene expression 
during myeloid cell development [27]. It can modulate 
the expression of at least 3000 genes expressed in 
hematopoietic cells; there are more than 1000 direct target 
genes [29]. Tacstd2 could possibly be one of them. AP-1 is 
a downstream target of Trop2 expression [8]. C-Jun, which 
is part of the AP-1 transcription factor complex, functions 
as a critical co-activator of PU.1 transactivation of various 
myeloid promoters. Dysregulation of PU.1 activity can 
contribute to leukemogenesis [29].
6. WTl
WT1 (Wilms’ tumor suppressor gene) is critical 
for urogenital development and has a complex role 
in tumorigenesis, partly through the regulation of the 
G2/M transition [19]. WT1 suppresses cyclin E, whereas 
mTrop2 increases levels of cyclin E [8,30]. Trop2 is a 
calcium signal transducer and WT1-associated protein 
is a regulator of Ca2+ homeostasis [19,31]. WT1 directly 
binds to the AKT promoter and creates a positive feedback 
loop between WT1 and AKT expression via the P13K/
AKT pathway in lung cancer. High levels of WT1 IgG 
antibody expression in lung cancer is associated with a 
worse prognosis, but when Trop2 is increased in lung 
adenocarcinomas, it can suppress cancer progression, 
suggesting downregulation [7, 23]. In Wilms’ tumor, WT1 
suppresses the IGF-1R gene, while Trop2 lowers IGF-1R 
levels in lung cancer [7,33].
7. Glis2 
Glis2 is a Kruppel-like zinc finger transcription 
factor involved in kidney development; loss of it causes 
nephronophthisis through the induction of increased 
apoptosis and fibrosis [19]. Glis proteins have been 
hypothesized to be activated through post-translational 
modifications and subsequently translocated to the nucleus 
where they regulate transcription by interacting with Glis 
binding sites in the promoter regions of target genes [34].
Glis2 may act as a repressor of epithelial-
mesenchymal transition (EMT). Glis2 acts as a negative 
regulator of β-catenin and inhibits TCF/LEF signaling 
and the β-catenin -TCF/LEF mediated activation of cyclin 
D1 [34]. The nuclear ICD of Trop2 colocalizes with 
β-catenin in the nucleus and is involved in a cascade that 
upregulates cyclin D1 [10]. Thus, Trop2 and Glis2 have 
opposite effects on β-catenin. Lack of Glis2 may enhance 
the transcriptional activation of β-catenin and, therefore, 
promotes tumorigenesis and allows for Trop2-β-catenin 
localization in the nucleus [35].
8. AIRE 
AIRE is an autoimmunity regulator transcription 
factor [19]. AIRE promotes T-cell tolerance and 
prevents autoimmune diseases. Deficiencies in AIRE 
cause elevated T-cell immune responses, which serve to 
suppress melanoma outgrowth [36]. If AIRE deficiencies 
allow cells to be more aggressive in their attacks and less 
tolerant, this may have a negative effect in some cancers. 
AIRE complexes with and influences the activity of 
many transcription factors. It interacts with the common 
coactivator CREB-binding protein (CBP), which is known 
to upregulate Trop2 [37,38]. By activating CBP, AIRE 
may be, thus, regulating Trop2, although it is not certain.
9. FOXM1
FOXM1 (forkhead box protein transcription factor) 
regulates G2-M transcription [19]. FOXM1 has been 
identified as one of the most commonly upregulated 
genes in human solid tumors [39]. It has stem cell-like 
properties, as does Trop2. Phosphorylation of FOXM1 
via the RAF/MEK/MAPK pathway stimulates FOXM1. 
Nuclear FOXM1 is functionally activated in tumor cells. 
Trop2’s downstream ERK and Raf pathways could 
phosphorylate FOXM1, suggesting a positive feedback 
relationship [8].
FOXM1 knock-down leads to decreased expression 
of p27, while Trop2 expression downregulates p27 
[8,39]. FOXM1 overexpression contributes directly to 
metastatic behavior by driving the EMT through AKT 
[39]. In lung tumorigenesis, Trop2 actually attenuates 
AKT expression and its downstream targets [7]. FOXO3a 
negatively regulates FOXM1 target gene expression. 
Nuclear accumulation of FOXO3a can repress FOXM1 
and induce cell death [39]. Trop2 downstream effectors 
can induce phosphorylation of FOXO3a. Heightened ERK 
activity could lead to a pathway that ends in proteasomal 
degradation of FOXO3a, which would then prevent the 
negative regulation of FOXM1 by FOXO3a [8].
10. FOXP3
FOXP3 is another forkhead box protein transcription 
factor that is associated with metastatic disease. 
Inactivation of FOXP3 modulates Trop2 expression via 
an indirect mechanism [19].
Expression of Trop2 in Cancer and its Prognostic 
Significance
Overexpression of wild-type Trop2 is shown to 
be necessary and sufficient to drive cancer growth [40]. 
Trop2 is implicated in the activation of the ERK/MAPK 
pathway, leading to downstream alterations in cellular 
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proliferation, migration, invasion, and survival of cancer 
cells [41]. Trop2-driven signaling is essential for the 
growth of human cancer cells in vitro and in pre-clinical 
models [19]. It has a role in accelerating the cancer cell 
cycle and cell growth stimulation [14].
Trop2 overexpression is associated with decreased 
patient survival as well as increased tumor aggressiveness 
and metastasis in many cancers. EpCAM and Trop2 are 
similarly expressed in many small-sized pulmonary 
adenocarcinomas: the expression of EpCAM is 
significantly related to a favorable outcome, while Trop2 
expression tends to indicate an unfavorable outcome [14].
Trop2 is overexpressed by various human 
carcinomas including, breast, cervix, colorectal, 
esophagus (some types), lung (some types), non-
Hodgkin’s lymphoma, chronic lymphocytic lymphoma 
(CLL), Raji Burkitt lymphoma, oral squamous cell, 
ovarian, pancreatic, prostate, stomach, thyroid, urinary 
bladder, and uterine. Trop2 is not upregulated in the 
majority of esophageal, head, neck, and lung tumors and is 
not expressed in anaplastic large cell lymphoma (ALCL) 
[11,42]. Table 1 summarizes Trop2 expression in relation 
to specific cancers and its prognostic significance. Briefly, 
we present below the expression of Trop2 in various 
cancers:
A. Anaplastic large cell lymphoma (ALCL)
The absence of Trop2 in ALCL cells may indicate 
that it is not involved in tumor growth. Aberrant copies of 
the CCND1 / chromosome 11 may be observed in ALCL, 
probably as a consequence of the reported ploidy changes 
in these tumors. Aberrant cyclin D1 expression seems 
to promote proliferation in other types of lymphoma, 
while a growth promoting CCND1/Trop2 fusion product 
has also been described in these tumors. In ALCL, the 
ectopic expression of Trop2 would potentially indicate 
the presence of the CCND1/Trop2 fusion. However, since 
Trop2 is not present, therefore, ALCL tumors do not 
have CCND1/Trop2 fusion products [49]. The absence of 
Trop2 expression suggests that its expression may not be 
involved in tumor growth [13].
B. Breast cancer
Overexpression of Trop2 is found in BT272 breast 
cancer cells. ER-negative/HER2-positive tumors have 
higher Trop2 levels than ER-positive/HER2-negative 
cases. Lower levels of Trop2 are found in SKBR3, MDA-
MB-435, and MDA-MB-468 breast cancer cell lines [18]. 
The cyclin D1-Trop2 mRNA is a potent oncogene as it 
transforms primary cells in vitro and induces aggressive 
tumor growth in vivo in cooperation with activated RAS. 
Silencing of the chimeric mRNA inhibits the growth of 
breast cancer cells. The stabilized cyclin D1 mRNA 
cooperates with Trop2 in stimulating the growth of cancer 
cells [43]. Trop2 overexpression may be associated with a 
less favorable breast cancer phenotype [18].
C. Cervical cancer
Trop2 expression in cervical carcinoma is 
upregulated, but its expression is not vastly different 
from the Trop2 expression in normal cervical tissues [11]. 
The tumorigenic function of Trop2 in cervical cancer is 
associated with increased expressions of cyclin D1, cyclin 
E, CDK2, and CDK4, but reduced expressions of p27 
and E-cadherin via the activation of the ERK signaling 
pathway. Overexpression of Trop2 is closely related with 
the FIGO stage, histological grades, lymphatic metastasis, 
invasive interstitial depth and high expression of Ki-67. 
Significantly decreased overall survival and progression 
free survival have been noted in patients. Trop2 may be a 
prognostic indicator for cervical cancer [44].
D. Colon and colorectal cancer
Trop2 is overexpressed in colon and colorectal 
cancer [11,14]. Trop2 expression leads to decreased 
survival in colon cancer.[7]. High expression can indicate 
poor prognosis [45]. Trop2 is a significant predictor of 
poorer patient survival and relates to the chance of disease 
recurrence and liver metastasis in colon cancer [46]. 
Expression in left-sided colon cancer (LSCC) is much 
higher than in right-sided colon cancer (RSCC) and may, 
thus, be a potential independent prognostic factor of LSCC 
[45]. Trop2 expression is highly expressed in colorectal 
tumors and is associated with an unfavorable outcome also 
[47].
E. Endometrioid endometrial cancer (EEC) 
Trop2 may be clinically useful in the attempt to 
identify patients at higher risk of relapse before surgery, 
and subsequently, to optimize follow-up treatments. 
Trop2 is highly expressed in EEC. Its expression is 
much higher in poorly differentiated EEC as opposed to 
well-differentiated EEC. It is a marker for biologically 
aggressive tumor phenotypes and poorly differentiated 
EEC. It is an independent prognostic factor for poor 
disease-free survival and can prognosticate patient 
outcome [2].
F. Esophageal cancer 
Trop2 expression is detected on esophageal 
carcinomas [11]. Protein levels are much higher in 
esophageal squamous cell carcinoma lines than in normal 
tissues and are notably higher in mild hyperplasia of 
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Table 1: Trop2 Expression In Cancer 
Cancer Trop2 Expression Prognostic Significance [References]
Anaplastic large cell lymphoma (ALCL) No expression, implicating that its expression may 
not be involved in tumor growth 
No [13]
Breast 
Overexpression  in some types ; downregulated  in 
others Yes [18, 7]
Cervical carcinoma 
Overexpression Suggested [44]
Colon cancer Overexpression Yes [46, 11, 7, 45]
Colorectal carcinoma Overexpression Yes [14, 47]
Endometrioid endometrial cancer (EEC) Overexpression; higher tumor grade and cervical 
involvement 
Yes [2]
Esophagus Overexpression Suggested [48, 11]
Gastric cancer Overexpression Yes [49]
Glioma Overexpression Yes [50]
Head and neck squamous cell carcinoma Not upregulated on tumors No [11]
Hilar cholangiocarcinoma Overexpression Yes [51]
Kidney mRNA expression is downregulated Suggested [7]
Large intestine mRNA expression is upregulated  Suggested [7]
Lung and non-small cell lung cancer (NSCLC) Downregulated in most lung cell lines Yes, low Trop2 expression is significant [7, 11, 55]
Chronic lymphocytic lymphoma
(CLL) Overexpression Possible [56]
Extranodal NK/T-cell lymphoma, nasal type (ENKTL) Overexpression Yes [57]
Non-Hodgkin’s lymphoma (NHL) Overexpression Possible [12]
Small-sized Pulmonary adenocarcinoma Overexpression Yes [14]
Squamos cell carcinoma of the oral cavity Overexpression Yes [54, 14]
Ovarian Overexpression Yes [59, 11]
Pancreatic Overexpression Yes [60, 11]
Prostate Overexpression Yes [11, 7, 6, 62]
Stomach carcinoma Overexpression Suggested [11]
Thyroid carcinoma Overexpression Suggested [11]
Urinary bladder carcinoma Overexpression Suggested [11]
Uterine Overexpression Suggested [11]
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esophageal mucosae. mRNA expression of Trop2 is not 
noted to be elevated in cancer tissues or cell lines [48].
G. Gastric cancer
Trop2 is overexpressed in gastric cancer. Trop2 is 
an independent prognostic marker for disease recurrence 
in the intestinal type gastric cancer. In intestinal-type 
gastric cancer, Trop2 expression is correlated with shorter 
disease-free survival. Overall, Trop2 overexpression 
is predictive of overall survival and poor disease-free 
survival in lymph node positive patients [49].
H. Gliomas
Trop2 expression is overexpressed in gliomas. 
Trop2 expression is much higher in WHO grade II and 
IV gliomas than grade II gliomas. Trop2 correlates with 
Ki-67 and microvessel density (MVD), but not with age 
or gender in gliomas. Trop2 expression is correlated with 
malignancy, proliferation, and angiogenesis in gliomas 
and tends to increase with increasing WHO grades [50].
I. Squamous cell carcinoma of the head and neck
Expression of Trop2 is not upregulated in head and 
neck tumors compared to normal tissues [11].
J. Hilar cholangiocarcinoma
Trop2 is expressed in hilar cholangiocarcinoma. 
Trop2 correlates with microvessel density as well. Trop2 
expression has an independent prognostic value in patients 
with hilar cholangiocarcinoma. High Trop2 expression 
correlates with a much poorer overall survival rate than 
with low Trop2 expression [51].
K. Kidney cancer
Trop2 mRNA expression is downregulated in kidney 
cancer [7].
L. Squamous cell carcinoma of the oral cavity
Overexpression of Trop2 is found in oral squamous 
cell carcinomas [14]. The Tacstd2 gene is a direct target 
of miR-125b-1, which causes dysfunction of the mitogen-
activated protein kinase pathway (MAPK) by regulating 
Tacstd2 expression. Loss of miR-125b-1 may have a key 
role in the pathogenesis and progression of squamous cell 
carcinomas of the head and neck and potentially other 
tumors [52]. Trop2 loss fails to suppress keratinocyte 
transformation, which causes keratinocytes to pass through 
an EMT and form tumors. Total loss of Trop2 protein 
expression is observed in the spindle cell component of 
sarcomatoid carcinomas [53]. Trop2 expression has an 
unfavorable outcome [14]. High expression correlates with 
aggressiveness and poor prognosis. It is an independent 
prognostic factor of poor disease outcome and it correlates 
with worse survival [54].
M. Large intestine
Trop2 mRNA expression is upregulated in cancer of 
the large intestine [7]. A cyclin D1-Trop2 mRNA chimera 
is expressed by many gastro-intestinal cancers [11].
N. Lung cancer
Trop2 expression is not upregulated on the majority 
of lung tumors [11]. Low Trop2 expression is observed 
in lung adenocarcinoma tissues as compared with 
their normal counterparts. This could be due to loss of 
heterozygosity (LOH) or hypermethylation of the CpG 
island DNA of Trop2 upstream of the promoter region. 
Inactivation of Trop2 may play a role in lung cancer 
tumorigenicity through losing its suppressive effect on 
IGF-1R signaling and tumor growth. Tacstd2 is a potential 
tumor suppressor gene in lung cancer development. It has 
a potential suppressive role in malignancy [7].
Low expression of Trop2 is noted in in NSCLC in 
patients. It is downregulated in most lung cell lines except 
for H322M (adenocarcinoma), EKVX (adenocarcinoma), 
and HOP92 (large cell). Trop2 promotes cell proliferation 
and increases colony formation, thus resulting in cells 
increasing in volume. Downregulation of Trop2 by DNA 
hypermethylation or loss of heterozygosity (LOH) may 
lead to lung carcinogenesis [7]. Trop2 overexpression 
shows better survival in NSCLC in patients with 
adenocarcinoma and may be a better prognostic marker in 
advanced stage adenocarcinoma [55].
O. Lymphomas
Trop2 is overexpressed in chronic lymphocytic 
lymphoma (CLL), extranodal NK/T-cell lymphoma, nasal 
type (ENKTL), and non-Hodgkin’s lymphoma (NHL) 
[12,56,57]. Trop2 is overexpressed in extranodal NK/T 
cell lymphoma, nasal type (ENKTL) and is associated 
with lymph node involvement and poor overall survival. 
Trop2 expression reflects a more malignant phenotype and 
may be an unfavorable prognostic factor for ENKTL [57].
P. Small-sized pulmonary adenocarcinoma
Trop2 overexpression is found in nonlepidic-type 
tumors. Besides the cell membrane, Trop2 is additionally 
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expressed in the cytoplasm. Trop2 is associated with an 
unfavorable outcome and is an independent prognostic 
factor. It has the opposite effect of its homologue, 
EpCAM, which is associated with a favorable outcome. 
Trop2 expression is detected in more poorly differentiated 
tumors, which suggests that it may act as an oncogene 
[14].
Q. Ovarian cancer
Trop2 protein is overexpressed and Trop2 mRNA 
expression is upregulated in epithelial ovarian cancer 
[11]. Trop2 overexpression has been reported in serous 
ovarian cancer, a notably aggressive, treatment- resistant 
gynecologic malignancy. Trop2 expression was found 
in 82% of chemotherapy-resistant ovarian tumor tissues 
at mRNA and protein levels in one study. Eighty three 
percent of the ovarian cancer cell lines tested by qRT-PCR 
and flow cytometry demonstrated high Trop2 expression. 
Aberrant Trop2 expression may account for the enhanced 
invasive behavior and increased biologic aggressiveness 
of chemotherapy-resistant ovarian carcinomas [58]. 
Trop2 overexpression may correlate with an aggressive 
malignant phenotype for epithelial ovarian cancer and may 
be a novel prognostic factor [59].
R. Pancreatic cancer
Trop2 is overexpressed in pancreatic cancer [11]. 
High Trop2 expression is correlated with the development 
and malignancy of pancreatic cancer. It is associated with 
poor prognosis and could be a novel prognostic biomarker 
[60].
S. Prostate cancer
Trop2 mRNA expression is downregulated in 
prostate cancer [7]. Trop2 overexpression enhances 
directional cancer cell migration and is involved in the 
metastatic competence of prostate cancer cells [40]. It 
causes basal prostate cells to efficiently form spheres and 
express stem cell characteristics [61]. Trop2 is involved in 
the metastatic competence of prostate cancer cells. Trop2 
inhibits prostate cancer cell adhesion to fibronectin (FN) 
and, thus, promotes prostate cancer cell migration on 
fibronectin (FN). It enhances directional prostate cancer 
cell migration. Thus, Trop2 regulates prostate cancer cell 
adhesion to FN through activation of the P(1) integrin-
RACK1-FAK-Src signaling axis. Trop2 expression 
correlates with prostate cancer cell aggressiveness [62]. 
Prostate basal cells expressing high levels of Trop2 are 
able to efficiently form spheres and express stem cell 
characteristics [61].
T. Stomach carcinoma
Trop2 expression is upregulated [11]. The prognostic 
significance has not been reported.
U. Thyroid carcinoma
Trop2 expression is upregulated [11]. The prognostic 
significance has not been reported.
V. Urinary bladder carcinoma 
Trop2 expression is upregulated [11]. The prognostic 
significance has not been reported.
W. Uterine cancer 
Trop2 expression is upregulated in cancer of the 
uterus [11]. Trop2 overexpression has been reported in 
uterine serous papillary carcinoma (USPC), an aggressive, 
treatment-resistant cancer [58].
Trop2 and Drug Resistance
Several reports have suggested that Trop2 
expression regulates tumor cell resistance to therapeutic 
drugs. Postulated mechanisms by which Trop2 regulates 
resistance are briefly discussed below.
A. FOXM1 dysregulation
FOXM1 dysregulation is a major cause of 
tumorigenesis and drug resistance. It may possibly 
promote drug resistance by enhancing DNA damage 
repair. It is involved in cancer progression and has been 
identified as one of the most commonly upregulated genes 
in human solid tumors [39]. It is a transcriptional regulator 
of Trop2, thus, its dysregulation may potentially have an 
effect on Trop2 expression.
The accumulation of reactive oxygen species 
(ROS) can activate FOXM1 in a negative feedback 
loop to activate genes whose products are involved in 
antagonizing the oxidative stress. Tumor cells may hijack 
the negative regulation of FOXM1 by ROS in order to 
evade cytotoxic effects of chemotherapeutic drugs and to 
promote survival of resistant clones [39].
B. HOXA10 expression
Expression of HOXA10 (homeobox-leucine zipper) 
protein—another transcription factor of Trop2— has been 
associated with resistance to chemotherapy [23]. High 
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expression of HOXA10 causes resistance to combined 
chemoradiotherapy of concomitant and adjuvant 
temozolomide and radiotherapy in gliobastoma [63].
C. Tamoxifen resistance
The activation of Tacstd2 increases the cytoplasmic 
Ca2+ level, which could, in turn, activate CREB and the 
MAPK/ERK pathways through calmodulin-dependent 
protein kinases (e.g. CaMKII). The activated MAPK 
pathway can increase the expression of cyclin D1 
and cyclin E as well as reduce the level of the CDK 
(cyclin-dependent kinase) inhibitor, p27, to promote 
cell proliferation. The activated CREB can bind to the 
promoter of Tacstd2 and forms a positive feedback to 
promote and maintain the “on” state of Tacstd2. Resistance 
to the estrogen antagonist drug tamoxifen is associated 
with the high expression of c-Fos, AP-1 (activator 
protein 1) and pCREB activation, which could mediate a 
constitutive “on” state of Tacstd2, and thus could correlate 
with increased Trop2 expression [21].
D. Trastuzumab resistance
Trastuzumab is an anti-HER2 breast cancer drug. 
Monoclonal antibody resistance is associated with 
the dysregulation of p27 and activation of cyclin D/E. 
Activation of Tastd2 could modulate this dysregulation. 
Trastuzumab resistance is associated with increased cyclin 
E levels. Trop2 expression is known to inhibit p27, which 
can increase cyclin E levels, and may thus be a cause of 
this resistance [21].
E. Sensitivity to gefitinib in non-small cell lung 
cancer cell lines
A non-small cell lung cancer cell line found to be 
gefitinib-resistant had low levels of Trop2 expression. 
Alternately, flow cytometry analysis suggests that high 
levels are present. The reason for this discrepancy is 
unknown [58].
F. Resistance in ovarian and uterine cancers
Certain primary ovarian cancer cell lines were found 
to be highly resistant in vitro to multiple chemotherapeutic 
drugs including carboplatin, cisplatin, paclitaxel, 
doxorubicin, ifosfamide, gemcitabine and topotecan 
[58]. Uterine and ovarian carcinosarcomas, which are 
notoriously resistant to multiple clinically available 
chemotherapeutic agents, can be made highly sensitive 
to immune- mediated cytotoxicity when effector cells are 
engaged by the Trop2-specific antibody, hRS7 [64]. 
G. Head and neck cancer resistance to gefitinib 
and erlotinib
Common markers of resistance for epithelial growth 
factor receptor tyrosine kinase inhibitor drugs such as 
gefitinib and erlotinib for head and neck squamous cell 
carcinomas (HNSCC) and non- small cell lung carcinomas 
(NSCLC) include genes associated with the EMT, such as 
Trop2. Increased protein expression of vimentin combined 
with the loss of E-cadherin, claudin-4, and claudin-7 were 
associated with gefitinib resistance in both HNSCC and 
NSCLC cell lines. The loss of the Ca2+- independent cell-
cell adhesion molecules EpCAM and Trop2 in resistant 
lines was confirmed. The loss of Trop2 expression was 
more predictive of gefitinib resistance in NSCLC than 
HNSCC. Thus, the EMT may play a role in establishing 
gefitinib resistance for both HNSCC and NSCLC [65].
Pre-Clinical and Clinical Studies Targeting Trop2
A. Preclinical anti-Trop2 therapeutics
Tacstd2 is an oncogene with the potential as 
a therapeutic target, specifically for antibody-based 
therapy. Trop2 has restricted expression in normal tissues, 
therefore, anti-Trop2 therapeutics would be predicted to 
have limited toxicity, although there is still a possible 
risk of potential toxicity to healthy tissues that normally 
express Trop2 [11]. Its overexpression in metastatic 
tissues makes it an attractive and potential therapeutic 
target for late stage diseases [4]. Trop2 is overexpressed in 
primary tumors and has been proposed to be a marker for 
undifferentiated epithelial cells [7,19]. Table 2 summarizes 
in-vivo and in-vitro therapeutics.
B. In-vitro studies
1. Anti-Trop2 CTL
Human cytotoxic T lymphocytes (CTL) are able 
to recognize Trop2. Engineered professional antigen- 
presenting cells (APC) have been made that stimulate 
the growth and cytotoxicity of specific antitumor CTL 
in Trop2-expressing lymphomas in murine fibroblast 
and epithelial cell lines transfected with Tacstd2. These 
Trop2-specific CTL’s demonstrate high specific cytotoxic 
properties against their transfected target, Tacstd2 [66].
2. Ranpirnase (Rap)
Rap is an amphibian RNase that can act as an anti-
tumor agent and as an immunogen that will not cause 
any immune response in patients. A Rap fusion protein 
has been made with the anti-Trop2 antibody hRS7. In 
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lymphoma cell lines, 100% cell killing, in vitro, was 
established at concentrations greater than or equal to 1nM 
of the specific construct. This fusion protein has potential 
in inhibiting CLL and Raji Burkitt lymphomas [12].
3. (-)-Epigallocatechin-3-gallate (EGCG) 
EGCG is a green tea catechin that can act as an 
anti-tumorigenic agent, causing suppression of Trop2 
expression by affecting the post-transcriptional processing 
of Trop2 mRNA in SW480 colorectal cells lines. EGCG 
also affects Trop2 expression at the post-translational level 
in HCT-116 colorectal cancer cell lines. Treatment with 
EGCG causes rapid degradation of the Trop2 protein in 
colorectal cancer cells [47].
4. hRS7
hRS7 is a humanized monoclonal anti-Trop2 
antibody that can act as an inhibitor of cancer cell lines 
(OMMT, UMMT, EEC) and refractory cervical carcinoma 
[2,67,68]. Numerous hRS7 conjugate drugs also exist [69]. 
Incubation with hRS7 resulted in a high degree of immune-
mediated cell death in certain Trop2 overexpressing 
ovarian and uterine cell lines. Primary ovarian tumors 
showing high Trop2 expression, regardless of their 
serous or clear cell histology, are highly susceptible to 
hRS7- mediated antibody-dependent cellular cytotoxicity 
(ADCC) in the presence of effector cells in vitro. Although 
these tumor cells are resistant to multiple standard 
cytotoxic therapies in clinic studies, they remain highly 
sensitive to lysis by NK (natural killer) cells when these 
are engaged by hRS7. The administration of low doses 
of IL-2 in vivo may be a useful adjunct to increase the 
efficacy of hRS7 cytotoxicity in chemotherapy-resistant 
ovarian cancer patients. In EEC and refractory cervical 
cancer, hrS7 treatment also induces ADCC in Trop2 
expressing cancer cells. Negligible cytotoxicity against 
chemotherapy-resistant ovarian cancers was seen in the 
absence of hRS7 or in the presence of a rituximab control 
antibody [58].
5. Human Fab antibody against Trop2
The human Fab anti-Trop2 antibody inhibits the 
proliferation, induces the apoptosis and suspends the 
migration of MDA-MB-231Trop2-expressing breast 
cancer cells in a concentration-dependent manner. It is a 
promising therapeutic agent for breast cancers that express 
Trop2 [70].
6. Nano drug delivery of apoptosis activator 2
Nano drug delivery of apoptosis activator 2 to 
human gastric adenocarcinoma (AGS) cell lines with 
liposome targeted Trop2 antigens is a possible way 
for smart killing of AGS cells. The apoptosis activator 
2-loaded liposomes target cell surface Trop2 antigens in 
cancer cells and significantly increase apoptosis [71].
7. 5-Aza-2’-deoxycytidine
5-Aza-2’-deoxycytidine treatment on lung cancer 
cell lines CL1-5, and A549, reverses the hypermethylation 
of the Trop2 promoter CpG island and elevates both Trop2 
mRNA and protein expression in lung cancer cells. This 
increase in Trop2 expression suppresses lung cancer cell 
proliferation and colony formation and could, thus, be a 
therapeutic agent [7].
C. In vivo studies 
1. 131I-IMP-R4-hRS7
hRS7 (an anti-Trop2 monoclonal antibody) labeled 
with 131I-IMP-R4, has been developed and evaluated in 
preclinical radioimmunotherapy (RAIT) studies. Nude 
mice with established (0.3 cm) subcutaneous breast cancer 
MDA-MB-468 tumors received single administrations 
of either 131I-IMP- R4-hRS7 or 131I-hRS7 and led to 
a mean tumor volume 8 weeks post-treatment of 20% 
compared to 163% for 131I-hRS7 and 280%, respectively, 
for the control groups. Complete remission was reported 
in 5 out of 11 mice treated with 131I-IMP-R4-hRS7 [72].
2. 2L-Rap(Q)-hRS7
A novel IgG-based immunotoxin has been made, 
called 2L-Rap(Q)-hRS7, made of Rap(Q), a mutant Rap 
with the putative N-glycosylation site removed, and hRS7, 
an internalizing, humanized antibody against Trop2. This 
immunotoxin suppresses tumor growth in a prophylactic 
model of mice with human non-small cell lung cancer. 
2L-Rap(Q)-hRS7 could be a potential therapeutic for 
Trop2 expressing cancers, such as cervical, breast, colon, 
pancreatic, ovarian, and prostate. In NSCLC xenografts, 
this immunotoxin suppressed tumor growth, with an 
increase in the median survival time from 55 to 96 days 
(P<0.01) [73].
3. 90Y-Hpam4 RAIT (Radioimmunotherapy) with the 
hrs7-SN-38 conjugate
The humanized antibody 90Y-hPAM4 
(90Y-clivatuzumab tetraxetan), when combined with 
RAIT targets a pancreas cancer antigen, while the 
conjugate hRS7-SN-38 targets Trop2 on the tumor. This 
combination leads to a higher survival rate (100%) and 
greater tumor-free response in animals (90%) than with 
RAIT alone, which had an 80% survival rate and a 50% 
tumor free response in animals with tumors of NHL and 
pancreatic cancer [12].
4. Enveloped virus-Like particles (VLPs)
Immunization with mTrop2 VLPs led to a 
significant reduction in tumor growth accompanied by 
a broad activation and tumor infiltration of CD4 (+) and 
CD8 (+) T cells as well as natural killer and natural killer 
T cells in pancreatic cancer in mice. VLP immunization 
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Table 2: Trop2 Preclinical Cancer Therapeutics
Inhibitor/ Agent Cancer Testing Response References
In Vitro
Antigen-presenting cells (APC) Lymphoma 
Transformed murine 
fibroblast and 
eptihelial  cell lines
Stimulate growth and cytotoxic 
effects of Trop2-specific anti-
tumor cytotoxic lympocytes 
(CTL)
[66]
Rap (frog RNase) fusion  proteins: 22-rap, 
20-rap,  C2-rap,  74-rap,  14-rap, and E1-
rap 
Lymphoma Cell lines
100% cell killing; potential in 
inhbiting  CLL and Raji Burkitt 
lymphomas 
[12]
(-)-Epigallocatechin-3-gallate (EGCG)  Colorectal cancer Cell lines Supresses Trop2 expression  [47]
hRS7 
Ovarian carcinosarcoma (OMMT), 
uterine carcinosarcoma (UMMT), 
endometrial endometrioid carcinoma 
(EEC), cervical carcinoma refractory 
Cell lines
High level of immune mediated 
cell death in OMMT and 
UMMT;  induces antibody-
dependent cellular toxicity 
(ADCC) against OMMT, EEC, 
cervical cancer refractory 
[59, 68, 67]
Nano drug delivery of apoptosis activator 
2 Gastric  adenocarcinoma Cell lines
Increase apoptosis of cancer 
cells [71]
5-Aza-2’-deoxycytidine Lung Cancer Cell lines
Elevates Trop2 expression, 
which suppresses cell 
proliferation and colony 
formation 
[7]
Human Fab antibody against Trop2 Breast Cancer  Cell lines Induces apoptosis and inhibits proliferation of  cancer cells [70]
In Vivo
131I-IMP-R4-hRS7 Breast cancer Nude mice xenografts
Decreased tumor volume; 
complete remission in 45% of 
cases according to one study
[72]
2L-Rap(Q)-hRS7 
Cervical, breast, colon, pancreatic, 
ovarian, non-small cell lung and 
prostate; NSCLC 
Nude mice xenografts Suppresses tumor growth [73]
90Y-hPAM4 RAIT (radioimmunotherapy) 
with hRS7-SN-38 conjugate (ADC) 
Non-Hodgkin’s Lymphoma; 
pancreatic cancer Nude mice tumors
Higher survival rate wit(100%) 
h combination than with RAIT 
alone (80%)
[12]
Enveloped virus-like particles (VLPs) Pancreatic cancer (C57BL/6 tumors)
C57BL/6 tumor-
bearing mice  
Significant reduction in tumor 
growth;  activation of natural 
killer cells,  lymphocytes and 
antibodies with no autoimmunity 
[79]
Anti-Trop2 hRS7-SN-38 (CL2A-SN-38)
Calu-3 (NSCLC), BxPC-3, Capan-1 
(pancreatic adenocarcinoma), 
and COLO 205 (colonic 
adenocarcinoma) ; solid tumors
Nude mice xenografts; 




Significant antitumor effects at 
nontoxic doses when compared 
to nontargeting control antibody-
drug conjugates (ADCs) 
[69]
Human Fab antibody against the Trop2 
extracellular domain Breast cancer Nude mice xenografts Inhibited growth [70]
antiTrop2 monoclonal antibodies 
Endometrium, breast, head and 
neck, colon-rectum, stomach, lung, 
ovay, prostate, pancreas, kidney, 
cervix, and bladder (urothelial) 
tumors 
Nude mice xenografts Inhibition of tumor growth [76]
TF12 and IMP288 Prostate cancer Nude mice xenografts
High and fast accumulation 
in the tumor, with significant; 
improvement of survival 
[78]
Milatuzumab (antibody-drug conjugate 
[ADC] of the humanized anti-CD74 
antibody)
A-375 (melanoma), HuH-7 and 
Hep-G2 (hepatoma), Capan-1 
(pancreatic), NCI-N87 (gastric), and 
Raji Burkitt lymphoma
Nude mice xenografts Increased survival [79]
bsHexAbs Lymphoma SCID mice xenografts Increased survival; anti-
lymphoma activity  
[56]
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generated mTrop2-specific cytotoxic T lymphocytes and 
antibodies with no measurable induction of autoimmunity. 
It decreased the population of regulatory T cells and 
myeloid-derived suppressor cells inside the tumor tissue 
resulting in decreased levels of immunosuppressive 
cytokines like interleukin-10 and transforming growth 
factor-P while promoting the activation of immature 
macrophages and dendritic cells. VLP immunization with 
gemcitabine treatment increased the survival of tumor 
bearing mice [74].
5. Anti-Trop2 hRS7-CL2A-SN-38 antibody-drug 
conjugate (ADC)
SN-38, the active metabolite of the topoisomerase 
inhibitor irinotecan, has a derivative, CL2A that has been 
successfully conjugated to hRS7 to provide significant and 
specific antitumor effects against a range of human solid 
tumor types, specifically in the NSCLC cell line Calu-3, 
the pancreatic cancer cell lines Capan-1 and BxPC-3, and 
the colon cancer cell line COLO 205. It is well tolerated 
in monkeys and may work similarly in humans [69,75].
6. Human Fab antibody against the Trop2 extracellular 
domain
Trop2 Fab inhibited the growth of breast cancer 
xenografts and reduced expression of anti-apoptotic bcl-2 
while elevating the expression of pro-apoptotic Bax [70].
7. Monoclonal antibodies
There is a patent for anti-Trop2 monoclonal 
antibodies with high affinity that are able to recognize 
different regions of the Trop2 molecule and can, thus, 
be used in the treatment and diagnosis of endometrium, 
breast, head and neck, colon-rectum, stomach, lung, ovary, 
prostate, pancreas, kidney, cervix, and bladder (urothelial) 
tumors. Studies of mice injected with human tumors that 
express Trop2 showed that these monoclonal antibodies 
can inhibit the growth of tumors [76].
8. TF12 and IMP288
TF12, which is an anti-Trop2 x antihapten bispecific 
antibody, and 111In-IMP288, which is a radiolabeled 
hapten-peptide, show high and fast accumulation in 
the tumor, despite TF12’s internalizing properties. One 
cycle of treatment with TF12 and 177Lu-IMP288 showed 
significant improvement of survival compared to treatment 
with 177Lu-IMP288 alone in mouse prostate cancer (90 
vs. 67 days, p<0.0001) with no renal or hematological 
toxicities [77,78].
9. Milatuzumab
Milatuzumab is an antibody-drug conjugate (ADC) 
of the humanized anti-CD74 antibody. Milatuzumab-
doxorubicin was most effective in the lymphoma model 
in nude mice, whereas in A-375 and Capan-1 solid tumors, 
only milatuzumab-SN-38 showed increased survival and a 
therapeutic benefit. Despite much lower surface expression 
of CD74 than Trop2 or CEACAM6, milatuzumab-SN- 38 
had similar efficacy in Capan-1 as anti-Trop2-SN-38, but 
in NCI-N87, anti-CEACAM6 and anti- Trop2 conjugates 
were superior. CD74 is a suitable target for ADCs in some 
solid tumor xenografts, with efficacy largely influenced 
by uniformity of CD74 expression and with SN-38 
conjugates providing the best therapeutic responses; SN-
38 conjugates were preferable in solid cancers, such as 
melanoma, hepatoma, pancreatic, and gastric, whereas 
doxorubicin ADC was better in lymphoma [79].
10. bsHexAbs
Trop2 is one of the antibodies used in the 
construction of bsHexAbs, bispecific hexavalent 
antibodies, which use the Dock-and-Lock (DNL) method 
for therapy of treating malignancies [56]. DNL is a method 
for building bioactive molecules with multifunctional 
structures [80]. The C
K
-format has advantages over 
the CH3-format as revealed by preclinical results due to 
improved anti-lymphoma activity in vivo. BsHexAbs 
targets CD20 and CD22 in CLL and Raji Burkitt 
lymphoma cells and increases chances of survival based 
on mice xenograft experiments [56].
Clinical Trial with IMMU-132: Phase I/II Study 
of IMMU-132 in Patients With Epithelial Cancers 
IMMU-132, which targets the Trop2 antigen, is 
being evaluated as a single agent in previously treated 
patients with advanced epithelial cancer including 
ovarian, breast (triple negative), prostate (hormone 
refractory), lung (non-small cell and small cell), head 
and neck (squamous cell), esophageal, gastric, colorectal, 
pancreatic, hepatocellular, renal (clear cell), and bladder 
cancer. The antibody, RS7, is attached to SN38, which 
is the active metabolite of irinotecan. This is for Stage 
IV, metastatic disease for patients who have been treated 
previously [81].
CONCLUDING REMARKS
Several antibodies, conjugates, and combination 
therapies have been developed and implemented in in vitro 
studies and in animal studies, with therapeutic outcomes. 
Trop2 can be targeted in order to identify its expression 
level and, thus, the severity of a specific cancer or it can 
be targeted in order to decrease its expression and, thus, 
to inhibit tumor progression and decrease tumor size. 
A human clinical trial is under way for phase I and II 
treatments of Trop2-expressing epithelial cancers with 
the antibody conjugate, IMMU-132. Trop2 has a lot of 
potential as a cancer therapeutic agent. Further, Trop2 




The Trop2-mediated signaling pathways and 
transcription factors that regulate its expression are 
still unclear. An expansion of the mechanisms of Trop2 
regulation and miRNA regulation of Trop2 expression 
along with the targeted genes are warranted for further 
investigations. Research comparing the direct targeting of 
Trop2 as opposed to targeting other factors that regulate 
Trop2 would be helpful. Elucidating the differences of 
Trop2 expression (over or under expression) in certain 
cancers and disease stages would be vital to uncovering 
the exact role of Trop2 in cancer growth and metastasis. 
The development of novel Trop2 therapies for later 
stages of cancers as well as therapies that do not induce a 
toxicity risk to normal Trop2-expressing tissues are vital. 
Immunotherapy specific for Trop2 can be developed, 
via specific epitopes as well as immuno-conjugates. 
Combination therapies have a lot of potential, for instance, 
the use of agents targeting Trop2 along with conventional 
chemotherapy, immunotherapy, radioimmunotherapy 
(RAIT), and chemical inhibitors are warranted 
investigations in pre-clinical and clinical studies.
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